Home > Search Results

An infectious fungal disease that occurs most often in the skin, ears, nasal sinuses, and lungs of people with suppressed immune systems.

Results: 7

Antifungal drugs (azoles) for allergic bronchopulmonary aspergillosis associated with asthma

Allergic bronchopulmonary aspergillosis is a condition that complicates some people with chronic asthma. Standard treatment for this condition is high doses of oral steroids. The azole antifungal drugs attack the fungus that causes this condition and short term studies suggest that they may have some benefit when added to standard therapy.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Treatments to fight fungal infections which cause allergic bronchopulmonary aspergillosis in people with cystic fibrosis

We planned to review evidence about the effect of treatments to fight fungal infections which cause allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Measurement of serum galactomannan to detect invasive aspergillosis in immunocompromised patients

When the immune system of a patient is unable to fight infections (for example because of prolonged corticosteroid therapy, immunosuppressive drugs, haematological malignancies or HIV/AIDS) invasive or systemic aspergillosis can be a life‐threatening mycotic (fungal) infection. Establishing a diagnosis of invasive aspergillosis at an early stage of infection allows early antifungal treatment, but a definitive diagnosis can only be established after death. To enable early diagnosis in a way that is not burdensome for the already weakened patient, galactomannan testing may be promising. Galactomannan is a cell wall component of Aspergillus that is excreted by the fungus.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Use of anti‐IgE treatment for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

We reviewed the evidence about the effect of anti‐IgE therapy for treating allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

A new, non‐invasive diagnostic blood test ‐ polymerase chain reaction ‐ for people at risk of an invasive mould infection (aspergillosis)

Review question. We planned to review the evidence about the accuracy of polymerase chain reaction (PCR) tests for diagnosing invasive aspergillosis (IA) in people with defective immune systems from medical treatment such as chemotherapy or following organ or bone marrow transplant.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

Is voriconazole better than amphotericin B or fluconazole to prevent and treat fungal infections in cancer patients with poor immune defence systems

Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of fungal infections. Such infections can be life‐threatening. Antifungal drugs are therefore often given to prevent fungal infections in such patients, either when these patients are known to have a fungal infection or when such an infection is suspected. We reviewed the evidence about the effect of voriconazole compared to amphotericin B or fluconazole to prevent or treat fungal infections in cancer patients with a poor immune system to provide defence.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Antifungal agents for infants and children with invasive fungal infections

Invasive fungal infections are a significant problem for children whose immune system is not functioning properly. The majority of the children have cancer. Antifungal medications can be given when these children develop a fever (for example a fever occurring when the white cells or neutrophils are low during chemotherapy) or when an infection has been formally identified (as in candidaemia, candidiasis and invasive aspergillosis). The antifungal agents that were compared appear equally efficacious. Pooling the data from the few studies that were available suggest kidney damage was less likely with a lipid preparation of amphotericin B compared with conventional amphotericin B. It is reasonable to recommend a lipid preparation of amphotericin B, if cost permits. No significant differences have been observed in children when other antifungal agents have been compared. More studies in children evaluating available antifungal are required to further clarify any benefits with regard to the risk of dying, prospects of complete recovery and drug toxicities.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

Systematic Reviews in PubMed

See all (212)...

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...